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ABSTRACT
Methylation at the 5-position of cytosine is a well-
studied epigenetic pathway. In addition to
5-methylcytosine (5mC), substantial amounts of
5-hydroxymethylcytosine (5hmC) also referred to
as the sixth DNA base have been detected in
certain tissues, most notably the brain. However,
the genomic distribution of this cytosine modifica-
tion is unknown. Here, we have used an immuno-
precipitation technique (5hmC-IP) to examine the
occurrence of 5hmC in DNA from human brain
frontal lobe tissue. The distribution of 5hmC was
compared to that of 5mC. We show that 5hmC is
more selectively targeted to genes than is 5mC.
5hmC is particularly enriched at promoters and in
intragenic regions (gene bodies) but is largely
absent from non-gene regions. 5hmC peaks at tran-
scription start sites did not correlate with gene ex-
pression levels for promoters with intermediate or
high CpG content. However, the presence of 5hmC
in gene bodies was more positively correlated with
gene expression levels than was the presence of
5mC. Promoters of testis-specific genes showed
strong 5mC peaks in brain DNA but were almost
completely devoid of 5hmC. Our data provide an
overview of the genomic distribution of 5hmC in
human brain and will set the stage for further func-
tional characterization of this novel DNA
modification.
INTRODUCTION
In mammalian cells, methylation of DNA at the
5-position of cytosine bases is an enzymatic process
targeted mainly to CpG dinucleotides. DNA cytosine
methylation is generally copied during DNA replication
in somatic tissues, is reversible during certain stages of
early development and is in some cases correlated with
modulation of gene expression (1,2). The initial forma-
tion and copying of 5-methylcytosine (5mC) patterns is
catalyzed by DNA methyltransferases (DNMT1,
DNMT3A and DNMT3B) (3,4). Patterns of 5mC, as a
stable epigenetic modiﬁcation of the genome, have been
investigated in many tissues using a variety of techniques
(5–7). Whereas the presence of 5mC at promoter CpG
islands is most often incompatible with gene transcription,
the reverse is true for gene bodies where the presence of
5mC is positively correlated with gene expression levels in
both plants (8,9) and mammals (10,11).
In 2009, Kriaucionis and Heintz and Tahiliani et al.
made the seminal discovery that another speciﬁc
modiﬁed DNA base, 5-hydroxymethylcytosine (5hmC) is
present in mouse Purkinje and granule neurons and in
embryonic stem (ES) cells (12,13). An enzymatic activity
involved in producing 5hmC from 5mC was identiﬁed as
the TET1 5mC oxidase (13). In the meantime, 5hmC also
has been detected at substantial levels in other mammalian
tissues and cell types (14–16). Furthermore, two mamma-
lian homologues of TET1, TET2 and TET3 have been
characterized and shown to possess similar catalytic
activities (17).
5hmC might serve unique biological roles. For example,
5hmC may be recognized by speciﬁc proteins that trans-
late a functional role of the modiﬁed base in gene control
mechanisms. In addition, it was shown that 5hmC inhibits
the binding of the methyl-CpG binding domain of MeCP2
(18), and of full-length MBD1, MBD2 and MBD4
proteins to DNA (19). Thus, 5hmC counteracts the role
of several 5mC-targeted transcriptional repressors, sug-
gesting a potential gene regulatory function of 5hmC.
Others have suggested that 5hmC might be an inter-
mediate in direct DNA demethylation (20,21), although
direct evidence for this pathway is currently not available
(16).
Since 5hmC is present in mammalian DNA at physio-
logically relevant levels and in a tissue-speciﬁc
manner (12–16), there is an important need to determine
the genomic location of 5hmC. Here, we have used
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map the distribution of this modiﬁed base in human
brain DNA.
MATERIALS AND METHODS
DNA samples
DNA from two frontal lobe brain tissues of accident
victims was obtained from Capital Biosciences
(Gaithersburg, MD, USA). Genomic DNA from mouse
ES cells was extracted by using the DNeasy Blood and
Tissue kit (Qiagen; Valencia, CA, USA). Genomic DNA
was fragmented by sonication to an average size of
 400bp using a Soniﬁer cell disruptor 350 (Branson;
Danbury, CT, USA).
Enrichment of 5hmC-containing DNA fragments with
anti-5hmC antibody
To characterize the anti-5hmC antibody, 76-mer oligo-
nucleotides (sequence 50-CCTCACCATCTCAACCAAT
ATTATATTACGCGTATATCGCGTATTTCGCGTTA
TAATATTGAGGGAGAAGTGGTGA-30) containing
C, 5mC or 5hmC at the six 50-CG sequences on each
strand were prepared as described previously (19).
Twenty-ﬁve picograms of each double-stranded 76-mer
were mixed with 0.4mg of sonicated genomic DNA from
mouse ES cells, denatured in 10mM Tris–HCl, 1mM
ethylenediaminetetraacetic acid buffer, pH 7.5 (TE
buffer), for 10min at 98 C and immediately chilled on ice
for 10min. The denatured DNA was immunoprecipitated
with control rabbit IgG or with a polyclonal anti-5hmC
antibody from Active Motif (Carlsbad, CA, USA) in
a ﬁnal volume of 200ml immunoprecipitation buffer
(10mM sodium phosphate, pH 7.0, 140mM NaCl
and 0.05% Triton X-100) by incubation for 2h at 4 C
on a rocking platform. To allow selective collection
of immuno-captured 76-mers, the mixtures were then
incubated with 10ml of magnetic Dynabeads M-280
sheep antibody against rabbit IgG (Dynal Biotech) for
2h at 4 C on a rocking platform and washed three times
with 700ml of immunoprecipitation buffer for 10min at
room temperature. The enriched DNA was puriﬁed using
QIAquick PCR puriﬁcation kit (Qiagen). The levels of
immuno-captured 76-mers were measured using quantita-
tive real-time PCR using the following conditions: 95 C for
3min followed by 50 cycles at 95 C for 10s and 50 C
for 45s with 0.6 U iTaq polymerase in an iQ5 real-time
PCR cycler (Biorad; Hercules, CA, USA), using the
forward primer 50-CCTCACCATCTCAACCAATA-30,
the reverse primer 50-TCACCACTTCTCCCTCAAT-30
and the probe 50-CGCGTATATCGCGTATTTCGCG-30
with 50-Cy5 and 30-Iowa Black RQ-Sp modiﬁcations (IDT;
Coralville, IA, USA). Data were analyzed with the iQ5
optical system software and displayed as percent by
referring to the level of 5hmC immuno-captured DNA.
Immuno dot blot assay
Genomic DNAs from human brain and mouse ES cells
were denatured in TE buffer for 10min at 98 C,
immediately chilled on ice for 10min and spotted onto a
charged nylon-based membrane. The membrane was
blocked with 5% non-fat milk at 4 C overnight. After
washing, the amount of 5hmC in genomic DNA was
detected using rabbit polyclonal anti-5hmC antibody
(Active Motif; 1:10000) followed by peroxidase-
conjugated anti-rabbit IgG (Jackson Laboratory; Bar
Harbor, ME, USA; 1:7000) secondary antibody. The
signal was visualized by using ECL-Plus (Amersham
Pharmacia Biotech).
Mapping of 5mC
Brain DNA (0.4mg) was fragmented by sonication to an
average size of  400bp. Enrichment of the methylated
DNA fraction by the methylated-CpG recovery assay
(MIRA) was performed as described previously (22).
NimbleGen tiling arrays were used for analysis of 5mC
and 5hmC genomic distribution (720k human CpG
island plus promoter arrays). The labeling of amplicons,
microarray hybridization and scanning were performed
according to the NimbleGen protocol. These arrays
cover all UCSC Genome Browser-annotated CpG
islands and the promoter regions for all RefSeq genes.
The promoter region covered is from  2440 to +610bp
relative to the transcription start sites (TSSs). For all
samples, the MIRA-enriched DNA was compared with
the input DNA.
Mapping of 5hmC
To map 5hmC in the human brain genome, at ﬁrst,
adaptor-ligated DNA fragments were prepared as
described previously with some modiﬁcations (22). Two
micrograms of sonicated DNA was end-repaired with T4
DNA polymerase (New England Biolabs; Ipswich, MA,
USA) to create blunt-ended DNA fragments by incuba-
tion for 20min at 12 C and puriﬁed using phenol/chloro-
form extraction and ethanol precipitation with 1mlo f
20mg/ml glycogen as carrier (Invitrogen; Carlsbad, CA,
USA). The blunt-ended DNA was incubated for 30min at
37 C with T4 polynucleotide kinase to phosphorylate the
50-ends. The DNA samples were puriﬁed again by phenol/
chloroform extraction. The end-repaired DNA fragments
were linker-ligated with 6mlo f5 0 mM double-stranded
adaptors as used in the MIRA protocol (22), 10  T4
DNA ligation buffer, 1ml of 400U/ml T4 DNA ligase
(New England Biolabs) in 50ml of total volume and over-
night incubation at 16 C, and then puriﬁed using
QIAquick PCR puriﬁcation kits (Qiagen). To ﬁll in the
overhangs, the adaptor-ligated DNA was incubated at
72 C for 10min in a reaction containing dNTP mix,
10  PCR buffer, 1.5mlo f5 U / ml Taq polymerase
(Qiagen) and puriﬁed using QIAquick PCR puriﬁcation
kit (Qiagen). The DNA was denatured in 200mlo fT E
buffer for 10min at 98 C and immediately chilled on ice
for 10min. An aliquot (20ml) of denatured DNA was
saved as input. The adaptor ligated and denatured DNA
was immunoprecipitated with anti-5hmC antibody as
described above in the 5hmC-enrichment assay with
some modiﬁcations. The DNA was incubated with 2ml
of rabbit polyclonal anti-5hmC antibody (Active Motif)
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allow selective collection of immuno-captured DNA, the
mixtures were then incubated with 15ml of magnetic
Dynabeads M-280 sheep antibody to rabbit IgG (Dynal
Biotech) for 2h at 4 C on a rocking platform and washed
three times with 700mlo f1   immunoprecipitation buffer
for 10min at room temperature. Washed beads were re-
suspended in 200ml of TE buffer with 0.25% sodium
dodecyl sulfate and 0.25mg/ml proteinase K (NEB) for
2h at 55 C and puriﬁed by phenol/chloroform extraction
and ethanol precipitation with 1ml of 20mg/ml glycogen
as carrier. The immuno-captured DNA was PCR
ampliﬁed in parallel with the input DNA, and then
analyzed on NimbleGen CpG island plus promoter
arrays as described above for the 5mC mapping assay.
For all samples, the 5hmC-enriched DNA was compared
with the input DNA. The microarray data were deposited
in the GEO database (accession number GSE27051).
Identiﬁcation and annotation of 5mC and 5hmC peaks
NimbleGen array data were normalized by the Loess
method and log2 ratios were calculated using the
Bioconductor ‘Limma’ package. Technical replicates of
5hmC arrays produced Pearson’s correlation coefﬁcients
between R=0.65–0.70; P<2.2 10e-16. Probes were
selected as positive if their log2 ratio was above the 95th
percentile of the ratios on the entire array (P<0.05). For
our analysis, we deﬁned a methylation peak as a region
with at least four consecutive positive probes allowing one
gap and covering a minimum length of 350bp. This strin-
gent peak deﬁnition will give few false-positive results,
with false discovery rate<0.05 estimated by repeating
the peak identiﬁcation using randomized log2 ratios on
the array. Identiﬁed peaks were mapped relative to
known transcripts deﬁned in the UCSC Genome
Browser HG18 RefSeq database. Methylation peaks
falling between  2.4kb upstream and +0.5kb down-
stream of TSSs were deﬁned as promoter peaks; those
falling within gene bodies (from 500bp downstream of
transcription start to 500bp upstream of transcript end)
were deﬁned as ‘intragenic’ peaks. Methylation peaks that
are >2440bp upstream and >500bp downstream of any
known transcripts were deﬁned as ‘intergenic’.
Identiﬁcation of 5mC-speciﬁc and 5hmC-speciﬁc peaks
Methylation peaks in 5mC and 5hmC samples were ident-
iﬁed as above. Speciﬁc peaks for NB1 and NB2 (two
normal brain samples from different individuals) were
identiﬁed separately. To identify 5mC-speciﬁc peaks, the
average log2 ratios of probes within each peak in the
5mC sample were compared with the average log2 ratios
of the same probes in the 5hmC sample, and the peaks were
considered as speciﬁc if the difference was more than 1. A
similar method was used to identify 5hmC-speciﬁc peaks.
Correlation between 5mC or 5hmC and gene expression
Promoters were classiﬁed into three categories reﬂecting
their CpG frequency, high-CpG (HCP), intermediate CpG
(ICP) and low CpG (LCP) according to Weber et al.’s
approach (23). To determine the relationship between
methylation or hydroxymethylation of cytosine at pro-
moters and expression levels of genes, we separated each
HCP, ICP and LCP promoter category into two sub-
categories, containing 5mC or 5hmC or not, based on
whether there was a peak overlapping with the promoter
region ( 2400 to+500 relative to the TSS). Gene expres-
sion data for frontal cortex tissue were downloaded
from Gene Expression Omnibus (GEO, accession
number GSE3790). The raw CEL ﬁles were processed by
the robust multi-array average (RMA) method imple-
mented in the Bioconductor ‘Affy’ package and the
average log2 intensity of each gene across all 30 samples
was calculated. For each promoter class, Student’s t-test
was applied to compare whether the expression values of
the genes with promoter cytosine modiﬁcation are differ-
ent from those of the genes without the modiﬁcations.
Gene ontology analysis
GeneontologyanalysiswasperformedusingDAVIDfunc-
tional annotation tools with Biological Process FAT and
Molecular Function FAT datasets. The enriched Gene
Ontology terms were reported as clusters to reduce redun-
dancy. The P-value for each cluster is the geometric mean
of the P-values for all the GO categories in the cluster. The
gene list in each cluster contains the unique genes pooled
from the genes in all the GO categories in the cluster. We
report all the clusters with P<0.05 except for 5mC
intragenic peaks, in which P<0.01 was used to save space.
Figure 1. Immunoprecipitation and immuno dot blot analysis of 5hmC
with a speciﬁc antibody. (A) Twenty-ﬁve picograms of 76-mer oligo-
nucleotides containing C, 5mC or 5hmC at identical CpG positions
were mixed with 400ng of sonicated mouse genomic DNA from ES
cells, incubated with anti-5hmC antibody and immunoprecipitated.
After immunoprecipitation and washing, the spiked target sequences
were ampliﬁed by quantitative real-time PCR and the speciﬁcity of
the immunoprecipitation reaction was determined. Normal rabbit IgG
was used as a control. (B) Immuno dot blot analysis of 5hmC in DNA
from mouse ES cells and in DNA from human brain frontal cortex. A
dilution series was used for semi-quantitative analysis of 5hmC levels.
Nucleic Acids Research, 2011,Vol.39, No. 12 5017RESULTS
Mapping of 5hmC in mammalian DNA
We used an antibody against 5hmC in immuno dot blots
and in immunoprecipitation experiments. Initially, we
veriﬁed that this antibody speciﬁcally immunoprecipitates
oligonucleotides containing 5hmC but not the same se-
quences containing cytosine (C) or 5mC (Figure 1A).
Immunoprecipitation was most effective when the DNA
was denatured. Using immuno dot blotting with the same
antibody, we veriﬁed that human frontal cortex DNA
contains about four-times higher levels of 5hmC than
mouse ES cells (Figure 1B) consistent with previous
results showing that 5hmC is abundant in brain tissue,
most notably in cortex DNA (15,16). We then proceeded
to map 5hmC in two different human brain DNA samples
derived from the frontal cortex. DNA was sonicated and
linker ligated, then denatured and immunoprecipitated
with anti-5hmC antibody. Immunoprecipitated frag-
ments and aliquots of input DNA were PCR ampliﬁed
using linker primers and analyzed on NimbleGen
720k CpG island plus promoter arrays interrogating
Figure 2. Mapping of 5hmC in human brain DNA. Several examples of mapping of 5hmC and 5mC in human brain DNA are shown. The blue
columns indicate the tiled regions. Green peaks reﬂect 5mC and blue peaks show the distribution of 5hmC peaks in each of two different normal
brain samples (NB1 and NB2). The TSSs and transcripts are indicated. The data are presented as P-value scores (-log10 of the P-value). (A) The
MCF2L gene on chromosome 13; (B) the CHST3 gene on chromosome 10; (C) an area of chromosome 10 is shown where several CpG islands are
located in a gene-free region. Such regions are often enriched for 5mC peaks but lack 5hmC. (D) The RNF220, TMEM53 and C1orf228 genes on
chromosome 1; (E) the PUF60, NRBP2 and EPPK1 genes on chromosome 8.
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spanning regions of  2.44kb upstream from the TSS to
+0.61kb downstream of the TSS. In parallel, we mapped
the distribution of 5mC using the MIRA, a technique,
which was established in our laboratory earlier
(10,22,24). This method is based on the MBD2 protein
as the methyl-CpG binding entity. MBD2-based DNA
methylation mapping techniques and those based on
immunoprecipitation with an antibody speciﬁc for 5mC
have very similar sequence coverage and are highly
concordant (25–27) although the exact concordance
may depend on experimental parameters such as salt
concentration used in the washing steps (28,29). We used
a medium salt concentration of 700mM. Log2 scatter
plots of the array data (Supplementary Figure S1) show
that the Pearson’s correlation coefﬁcient between the two
different brain samples (NB1 and NB2) is higher for 5mC
(R=0.81) than for 5hmC (R=0.61) but both data
sets are statistically highly correlated (P<2.2  10e-16).
The reason for this difference could be related to tech-
nical issues but it is also possible that variability is inher-
ently greater for 5hmC than for 5mC because 5hmC is a
secondary modiﬁcation that depends on the ﬁrst one
(5mC).
Figure 3. Distribution of 5hmC and 5mC peaks in the genome. The location of the respective peaks was assigned as being within the promoter,
intragenic, i.e. within gene bodies, or intergenic, i.e. not associated with genes. Two normal brain samples (NB1 and NB2) were analyzed for 5hmC
and 5mC. The pie chart at the bottom of the Figure indicates what percentage of sequences covered by the microarray probes fall into promoters,
intra- and intergenic categories.
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Figure 2 shows several snapshots of 5hmC mapping in
human brain DNA. Examples are presented where 5mC
and 5hmC either overlap or are more unique for each
modiﬁed base at speciﬁc locations. After Loess normaliza-
tion, peaks were designated as such when they had at least
four consecutive probes above the 95th percentile of the
log2 ratios allowing a one-probe gap. In total, we identi-
ﬁed about 2600 peaks for 5mC and between 1800 and 2100
peaks for 5hmC in each of the two brain samples. A list of
the peaks is shown in Supplementary Tables S1–S4. Peaks
were assigned according to their genomic location. For
5mC, slightly >20% of the peaks were at promoter
regions, deﬁned as  2.4kb upstream to 0.5kb down-
stream of the TSS, about 52–53% were intragenic and
approximately 25–26% were not associated with genes
(intergenic). For 5hmC, a higher percentage (55–59%) of
the peaks were at promoters, approximately 35–38% were
intragenic, i.e. in gene bodies, and only  6% were
intergenic (Figure 3). Although this distribution is
inﬂuenced by the array design, the result clearly shows
that 5hmC is targeted to genes, in particular promoters,
and is more selectively depleted from non-gene regions
than is 5mC.
Relationship between 5hmC and 5mC peaks
5hmC and 5mC peaks that overlapped by at least one base
were considered as common peaks. Figure 4 shows that
5hmC peaks and 5mC peaks overlap infrequently.
Intragenic peaks have more overlap between 5mC and
5hmC than promoter peaks and intergenic peaks (chi-
square test; P<2.2e-16 for 5hmC and P<1e-07 for
5mC). However, peaks at promoter regions rarely overlap
(Figure 4).
Correlation between 5hmC or 5mC at promoters and gene
expression
Using gene expression data of brain frontal lobe tissue
from public databases, we initially veriﬁed that genes
with 5mC peaks at promoters have lower gene expres-
sion levels than genes with no 5mC peak at the promoter
(Figure 5, bottom panels). This is true for promoters with
highCpG content (HCPpromoters) andintermediate CpG
content (ICP promoters) conﬁrming previous results
(23,30) but not for promoters with low CpG content
(LCP promoters). We then looked at possible correlations
between the presence of 5hmC peaks at promoters and ex-
pression levels. We did not ﬁnd any positive or negative
Figure 4. Overlap between 5hmC and 5mC peaks. The peaks found in two brain samples NB1 and NB2 were annotated to promoter, intragenic and
intergenic regions as described in the ‘Materials and Methods’ section. For each of the regions, peaks were considered as common between 5mC and
5hmC when they overlapped at least by 1bp. Intragenic peaks of 5hmC overlap more commonly with 5mC than 5hmC peaks in promoters or
intergenic regions do (chi-square test, P<2.2e-16).
5020 Nucleic Acids Research, 2011,Vol.39, No. 12correlation for HCP and ICP promoters (Figure 5, top
panels) although 5hmC peaks and gene expression levels
were positively correlated at LCP promoters.
Gene categories marked by 5hmC or 5mC at promoters
We conducted gene ontology analysis using the DAVID
interface to identify potentially interesting gene categories
characterized by 5hmC or 5mC peaks (but not both) in the
promoter. For promoter-associated 5hmC peaks, we
identiﬁed genes involved in muscle function, ion transport,
neuronal development and patterning processes as signiﬁ-
cantly enriched categories (Supplementary Table S5).
When we characterized genes with 5mC peaks at pro-
moters, we found that genes involved in male gamete
function andDNA packaging were most signiﬁcantly over-
represented (Supplementary Table S6). Testis-speciﬁc
genes and other germ line-speciﬁcally expressed genes are
often silenced by promoter DNA methylation in somatic
tissues (31). These same genes are remarkably devoid of
5hmC peaks at their promoters. Examples for three testis-
speciﬁc genes, FANK1, STK31 and ADAM3A, are shown
in Figure 6. The data suggest that testis-speciﬁc genes are
characterized by the absence of 5hmC at their promoters.
5hmC and 5mC in gene bodies
Genes with 5hmC peaks in gene bodies have higher ex-
pression levels than those without 5hmC peaks (Figure 7,
P<0.00001). This correlation is even more signiﬁcant than
the positive correlation between 5mC in gene bodies and
expression levels (P<0.00063 and P<0.00028 for NB1
and NB2, respectively). Gene ontology analysis indicated
that 5hmC-marked gene bodies include genes involved in
Figure 5. Correlation between 5hmC and 5mC peaks at promoters and gene expression levels. Gene expression data were obtained from GEO
dataset GSE3790. The raw CEL ﬁles were processed by RMA and average log2 intensities among biological replicates were calculated to represent
their expression levels. Genes were separated into groups having a peak for 5mC or 5hmC or not having a peak at their promoters. Gene expression
levels (log2 scale) were assigned for these two categories and represented as box plots and their difference was determined by Student’s t-test.
**P-values were signiﬁcant for 5mC at promoters with high and intermediate CpG contents (HCP and ICP, P<0.05 for both NB1 and NB2) but not
for low CpG (LCP) promoters (P>0.05 for both NB1 and NB2). For HCP and ICP promoters, there was no signiﬁcant difference between the
expression levels of 5hmC-marked promoters and other promoters (P>0.05 for both NB1 and NB2) but expression levels were positively correlated
for LCP promoters (P<0.05).
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scription and cell death, as well as other functions
(Supplementary Table S7). Data for genes with 5mC
peaks in gene bodies showed that genes encoding cell
adhesion molecules including the protocadherin family,
metal-binding proteins and ion channels were most
signiﬁcantly enriched (Supplementary Table S8).
Other signiﬁcantly enriched categories included proteins
involved in neuron development and neuronal
differentiation. Several of these groups of genes are
expected to be expressed and functionally important in
the brain.
DISCUSSION
In this article, we report one of the ﬁrst attempts to map
the genomic distribution of 5hmC in human genomic
DNA. We chose brain frontal cortex tissue, because the
Figure 6. Testis-speciﬁc genes are marked by 5mC at their promoters but lack promoter-associated 5hmC peaks. Three examples are shown for the
testis-speciﬁc genes FANK1, STK31 and ADAM3A, located on three different chromosomes. Green peaks reﬂect 5mC and blue peaks show the
distribution of 5hmC peaks in each of two different normal brain samples (NB1 and NB2). The TSS and direction of transcription are shown. The
blue columns indicate the tiled regions.
Figure 7. Positive correlation between 5hmC and 5mC in gene bodies and gene expression levels. Gene expression data were obtained from GEO
dataset GSE3790. The raw CEL ﬁles were processed by RMA and average log2 intensities among biological replicates were calculated to represent
their expression levels. Genes were separated into groups having peaks for 5mC or 5hmC or not having peaks in intragenic regions. Gene expression
levels (log2 scale) were assigned for these two categories and represented as box plots and their difference was determined by Student’s t-test.
P-values were highly signiﬁcant for 5hmC and expression levels (**P<0.00001) and signiﬁcant for 5mC and expression levels (*P<0.01).
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various regions of the brain, most notably the cortex
(12,14–16). The reason for the high levels of 5hmC in
this tissue, which has a low cell division rate, is currently
unknown. Perhaps it is the lack of cell division per se that
prevents dilution of oxidized 5mC by DNA replication,
and 5hmC can therefore accumulate over time. We at-
tempted to acquire clues as to the function of 5hmC in
brain DNA by mapping its distribution in different parts
of the genome using 5hmC-immunoprecipitation.
While 5mC and 5hmC peaks are often mutually exclu-
sive, this is not always the case and peaks of both modiﬁed
cytosine bases coexist at many genomic locations, for
example in gene bodies (Figure 4). However, we noticed
that 5hmC is more frequently targeted to promoters.
Despite of this, we did not ﬁnd a positive (or negative)
correlation between 5hmC peaks at promoters and gene
expression levels for HCP and ICP promoters, although a
positive correlation existed for LCP promoters. One po-
tential model for the existence of 5mC oxidation at pro-
moters could be that this pathway may represent a ‘repair’
process that is aimed at keeping promoter CpG islands
largely free of DNA methylation introduced by errors
due to aberrant de novo methylation of CpG islands by
DNA methyltransferases. Interestingly, the TET1 protein
contains a CXXC domain (13), a domain known to bind
to unmethylated CpG sites, which are present abundantly
in CpG islands. 5mC oxidation can neutralize the repres-
sive function of DNA CpG methylation, for example by
disallowing the binding of methyl-CpG binding proteins,
as we previously reported (19), thus maintaining an open
chromatin conﬁguration. Since we did not ﬁnd a strict
correlation between 5hmC peaks at promoters and gene
expression levels, this situation may apply to active, poised
and inactive genes having unmethylated CpG islands at
their promoters.
Gene ontology analysis for 5hmC in promoters revealed
a group of genes involved in ion transport, nerve function
and several other categories. When analyzing gene cate-
gories marked or not marked by 5hmC, we noticed a
striking absence of 5hmC from the promoters of testis-
speciﬁc genes that are highly methylated and have strong
5mC peaks at their promoters. This ﬁnding suggests that
these sequences, perhaps in association with speciﬁc chro-
matin marks, are refractory to modiﬁcation by the TET
oxidases.
5hmC is largely absent from intergenic regions
(Figure 2). Thus, in comparison to 5mC, 5hmC is more
selectively targeted to genes. This suggests that there is a
mechanism that targets TET proteins to presumably active
genes.
We also found substantial amounts of 5hmC in gene
bodies, in which 5mC tends to be enriched as well, as
previously reported (10,32,33). While this article was in
preparation, another group using chemical labeling and
biotin enrichment of 5hmC-containing DNA fragments
reported similar enrichment of 5hmC in gene bodies of
mouse cerebellum (34). The function of 5mC in gene
bodies, although found in many tissue types and organ-
isms (32), is currently unknown. It has been proposed that
5mC in gene bodies may prevent inappropriate
transcription initiation, for example by suppressing noise
transcription and/or antisense transcription (2,10).
Interestingly, we found that 5mC is particularly enriched
in those genes, which encode proteins with function in
neurons and other cells of the nervous system, such as
ion channel proteins and cell adhesion molecules
(Supplementary Table S8). Why some of the 5mC in
gene bodies is further modiﬁed to form 5hmC and what
the speciﬁc role of this process could be is unclear at this
time. We observed that there is a stronger positive correl-
ation between 5hmC in gene bodies and transcript levels
than there is for 5mC and transcript levels (Figure 7),
suggesting that 5hmC may be more potent than 5mC in
preventing inappropriate intragenic transcription initi-
ation. Further work will be required to determine how
the 5mC oxidases are targeted to genes, including pro-
moters and gene bodies, and what the precise molecular
function of 5hmC in these speciﬁc genomic locations
might be.
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